| 描述信息 |
Purpose: Periodic fluorodeoxyglucose (FDG) positron emission tomography (PET)-computed tomography (CT)/CT-Based response examinations are the current standard for clinical assessment of lymphoma treatment response. In this prospective study, we applied a blood-based multi-omics test, SeekInClarity, to assess treatment response and predict patient therapeutic outcomes in the major types of lymphoma.Experimental Design: We prospectively recruited 116 lymphoma patients from two clinical centers and collected blood samples at pre-treatment (baseline) and after two cycles of treatment (landmark) to calculate molecular tumor burden (MTB) score via the SeekInClarity analysis. The "molecular response" framework, developed based on the MTB dynamic changes between baseline and landmark, was used to predict treatment efficacy early across various first-line regimens. Results: Advanced tumor stages correlated with higher MTB scores, with MTB+ ratios of 31.8%, 63.6%, 84.6%, and 91.2% for stage I, II, III, and IV, respectively. After two cycles of treatment, MTB+ patients had significantly worse PFS (HR 0.13, 95% CI 0.05 - 0.33, P < 0.0001) and OS (HR 0.24, 95% CI 0.06 - 0.97, P < 0.05) compared to the MTB- patients. Multivariable Cox regression analysis demonstrated that molecular response was the strongest independent predictor of treatment efficacy, outperforming the Lugano classification, LDH, and B2M levels. Among patients with initial radiologic stable disease (SD) or partial response (PR), 16 progressed within 31.7 months, while 68.5% were classified as non-responders at the landmark. Conclusions: This study demonstrates the utility of molecular response based on SeekInClarity for early prediction of treatment efficacy and serves as a valuable complementary tool for identifying non-responders among patients with initial radiologic SD or PR. |
